Skip to main content

Charles River Laboratories Q3 FY2026 results

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$337.97−0.83%Close 13 Nov 2026 · Market value $16.04B

Charles River Laboratories reported revenue of $983 million, down 2.2% from a year earlier, net income of $333 million and diluted earnings per share of $6.86 against $1.10 for the third quarter of fiscal 2026 (the three months to 26 Sep 2026).

From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 26 Sep 2026, against the three months to 27 Sep 2025. Amounts in USD.

Charles River Laboratories Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$982.7M$1.00B−2.2%
Gross profit$357.9M$338.8M+5.6%
Gross margin36.4%33.7%+2.7 pts
Operating income$202.6M$133.8M+51.4%
Operating margin20.6%13.3%+7.3 pts
Net income$333.1M$54.42M+512%
Diluted EPS$6.86$1.10+524%
Operating cash flow$254.1M$213.8M+18.8%
Capital expenditure$46.81M$35.58M+31.6%
Free cash flow$207.3M$178.2M+16.3%

Operating KPIs for the quarter

Charles River Laboratories operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Organic revenue (change on a year)5.9%down 0.6 points
Remaining performance obligations$675.3Mup 4.0%
Cost of services provided (excluding amortization of intangible assets) revenue$780.3Mdown 3.4%
Cost of products sold (excluding amortization of intangible assets) revenue$202.4Mup 2.8%
DSA revenue$596.3Mdown 0.7%
RMS revenue$207.5Mdown 2.8%
Manufacturing revenue$178.9Mdown 6.2%
United States revenue$541.7Mup 0.8%
Europe revenue$240.1Mdown 13.5%
Canada revenue$120.6Mup 3.2%
Asia Pacific revenue$61.6Mup 19.3%

Earlier quarters

Charles River Laboratories results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202626 Sep 2026$982.7M−2.2%$6.86
Q2 FY202627 Jun 2026$1.00B−2.7%−$0.03
Q1 FY202628 Mar 2026$995.8M+1.2%−$0.30
Q4 FY202527 Dec 2025$994.2M−0.8%−$5.62
Q3 FY202527 Sep 2025$1.00B−0.5%$1.10
Q2 FY202528 Jun 2025$1.03B+0.6%$1.06
Q1 FY202529 Mar 2025$984.2M−2.7%$0.50
Q4 FY202428 Dec 2024$1.00B−1.1%−$4.20

More on Charles River Laboratories: financial statements · revenue · earnings per share

CRL's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.